Scientists at Sanford Burnham Prebys Medical Discovery Institute, University of California San Diego School of Medicine and Hopp Children’s Cancer Center Heidelberg (KiTZ) have demonstrated that personalized drug screens can be used to identify new therapeutic candidates for medulloblastoma. The approach measures the effectiveness of therapeutics using tumor cells obtained from a biopsy and can be performed in a few days—making it one of the quickest sources of information used in clinical decision-making.
Researchers reporting in ACS’ Nano Letters have developed nanoparticles that release bursts of calcium inside tumor cells, inhibiting drug pumps and reversing MDR.
Our ability to predict who will get cancer, how patients will respond to treatment, or if patients will relapse is still quite limited, despite advances in the detection of genetic mutations and the establishment of risk factors; recently researchers were inspired to find new ways of looking at the problem. In Biomicrofluidics, they report that using cellular mechanophenotyping, along with traditional methods such as immunostaining and genetic analysis, may provide a more comprehensive view of a tumor.